Status:
ACTIVE_NOT_RECRUITING
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
Lead Sponsor:
The Netherlands Cancer Institute
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Rectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
Detailed Description
38 patients with resectable rectal cancer will be enrolled. All patients will be treated with radiotherapy followed by bevacizumab and atezolizumab.
Eligibility Criteria
Inclusion
- signed informed consent
- patients age 18 years and older
- histologically confirmed adenocarcinoma of the rectum
- intermediate risk rectal cancer or low risk distal rectal cancer
Exclusion
- evidence of metastatic disease
- prior radiation therapy for disease under study
- prior treatment with CD137 agonists or immune checkpoint blockade therapies
- current or recent use of acetylsalicylic acid
- history of clinically significant cardiac or pulmonary dysfunction pregnancy or breastfeeding
- significant auto-immune disease
Key Trial Info
Start Date :
October 22 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04017455
Start Date
October 22 2019
End Date
August 31 2025
Last Update
June 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Marieke van de Belt
Amsterdam, North Holland, Netherlands, 1066CX